Meeting
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
Authors
Matthew Scott Ernst
Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
Matthew Scott Ernst , Vishal Navani , J Connor Wells , Frede Donskov , Naveen S. Basappa , Chris Labaki , Sumanta K. Pal , Luis A Meza , Lori Wood , D. Scott Ernst , Bernadett Szabados , Rana R. McKay , Francis Parnis , Cristina Suárez , Takeshi Yuasa , Anil Kapoor , Ajjai Shivaram Alva , Georg A. Bjarnason , Toni K. Choueiri , Daniel Yick Chin Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 308)
DOI
10.1200/JCO.2022.40.6_suppl.308
Abstract #
308
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.
First Author: Neil J. Shah
Poster
2021 Genitourinary Cancers Symposium
Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
First Author: Daniel M. Geynisman